Concentration of plasminogen and antiplasmin in plasma and serum

SA CEDERHOLM-WILLIAMS

From the Department of Haematology, John Radcliffe Hospital, Oxford

SUMMARY The concentrations of plasminogen and fast-acting antiplasmin were measured in 65 normal plasmas and matched sera. Concentrations were decreased in serum by 38% for plasminogen and 32% for fast-acting antiplasmin. The decrease in plasminogen level was due to both adsorption of plasminogen to fibrin and reaction with antiplasmin.

Wiman and Collen proposed a new model for the mechanism of fibrinolysis which in part relies upon the specific association of plasminogen with fibrin. This feature of the model had been proposed some 20 years earlier but had been criticised by some workers who claimed that plasma and serum plasminogen concentrations were identical and that very little plasminogen could be extracted from ex vivo thrombi. Light was shed on this problem when it was shown that plasminogen gains an increased affinity for fibrin following the loss of an N-terminal peptide. It is now clear that plasminogen and plasmin possess specific fibrin binding sites which interact with the antifibrinolytic lysine analogues.

The lysine binding sites of plasmin are also important in the reaction between plasmin and the primary plasmin inhibitor, alpha-2-antiplasmin. This inhibitor exercises a most effective control over plasmin by inactivating the enzyme at such a fast rate that free plasmin has only a very brief existence in plasma. Plasmin inactivation is one of the fastest known protein-protein interactions and the speed of the reaction is determined by the lysine binding sites of plasmin. Since these sites are occupied when plasmin(ogen) is bound to fibrin the bound enzyme is protected from the antiplasmin.

The plasma and serum concentrations of plasminogen and antiplasmin were re-examined in the light of this new model for fibrinolysis which itself is based upon the properties of the newly discovered alpha-2-antiplasmin. Recently developed techniques for the measurement of plasminogen and antiplasmin were also applied in this study to determine whether sufficient quantities of plasminogen naturally bind to fibrin to induce subsequent clot lysis after the exposure to plasminogen activator.

Material and methods

Plasma and serum samples were collected from 100 blood donors at a single blood donation session. After the withdrawal of 420 ml blood a further two lots of 9 ml each were collected into tubes containing 1 ml trisodium citrate (0-1 mol/l) or NaCl (0-1 mol/l). All samples were then stored overnight at 4°C for 15 h, after which time they were centrifuged at 4000 g for 30 min and 2 ml of the top layer of plasma or serum removed. This aliquot was divided into two equal portions, one lot pooled and both lots stored at −30°C until assayed. If a blood sample did not correspond exactly to the 1 ml calibrated mark on the tube, then both plasma and serum samples were discarded. Thirty-six such samples were discarded.

Plasminogen assay was carried out by a Gilford enzyme rate analyser (Gilford Inc., Ohio) with the method described by Friburger and Knos. Streptokinase and the chromogenic substrate D-valyl-D-leucyl-L-lys-p-nitroanalide were both purchased from KabiVitrum, London. Total antigenic levels of plasminogen were also measured using radial immunodiffusion plates (Hoechst Pharmaceuticals Ltd, Hounslow). Results were expressed as percentages of pooled normal plasma.

Fast acting antiplasmin was assayed using the Coatest antiplasmin assay kit (KabiVitrum Ltd, London) adapted directly for use on the Gilford enzyme rate analyser. This assay gives results which are directly proportional to the levels of alpha-2-antiplasmin concentrations. Results were expressed as percentages of pooled normal plasma.

Fibrinogen concentrations were measured by reference to a standard curve constructed from a reference

Other reagents used were 6-aminohexanoic acid (Koch Light Ltd, Colnbrook) and bovine thrombin (Diagen Diagnostics, Thame).

Results

The concentration of plasminogen and antiplasmin in normal plasma and serum samples is shown in Table 1. When compared to plasma levels the plasminogen concentration was reduced by some 38% in serum and antiplasmin by some 32%. Antigenically detected plasminogen was reduced by only 16% in serum. The plasma fibrinogen concentrations were 206 ± 59.3 mg/dl (6.08 μmol/l).

To determine the quantity of plasminogen bound to fibrin via the lysine sensitive fibrin binding site the following experiment was performed. Pooled plasma (65 samples) was mixed with 6-aminoheptanoic acid to a final concentration of 180 mmol/l and clotted with one unit of thrombin per ml of plasma and incubated at room temperature for 60 min. Plasminogen assays were performed on the plasma and serum and upon pooled serum to which 6-aminoheptanoic acid (180 mmol/l) had been added (Table 2). Functional plasminogen was reduced by 26% in the freshly prepared serum.

Discussion

When blood was allowed to clot for 15 h at 4°C the concentrations of functional plasminogen and antiplasmin are reduced in serum by some 38% (0.61 μmol/l) and 32% (0.32 μmol/l) respectively. The antigenically determined plasminogen on the other hand was only reduced by 16% (0.26 μmol/l). This discrepancy between functional and antigenic concentrations of plasminogen is possibly due to the radial immunodiffusion technique detecting both free plasminogen and plasmin-antiplasmin complexes.

Since the reaction between plasmin and alpha-2-antiplasmin occurs on a 1:1 basis a reduction in the normal 1 μmol/l concentration of antiantiplasmin by 32% (0.32 μmol/l) represents a similar reduction in plasminogen of 0.32 μmol/l. Thus the reduction of serum plasminogen appears to be due to two processes; 20% (0.32 μmol/l) by reaction with antiplasmin and the remaining 18% (0.29 μmol/l) by fibrin binding. This view is supported by the discrepancy in the antigenically determined plasminogen concentration which is reduced by only 16% (0.26 μmol/l) and by the finding that when serum is produced from pooled plasma in the presence of 6-aminoheptanoic acid (which prevents the binding of plasminogen to fibrin) the reduction in serum plasminogen is 26% (0.42 μmol/l). This difference suggests that some 14% (0.22 μmol/l) of plasminogen has been removed on the fibrin clot.

The activation and subsequent inhibition of 20% (0.32 μmol/l) of the plasminogen probably occurred during the 15 h incubation period in the presence of the blood cells. Evidently a small proportion (14–18%) of plasminogen binds to fibrin during the clotting of normal blood but whether this quantity (molar ratio of plasminogen: fibrin is 1:20) is sufficient to cause complete fibrinolysis in the presence of plasminogen activators and antiplasmins remains to be determined.

Thanks are due to the staff of the Regional Transfusion Centre at this hospital for the collection of

Table 1 Concentrations of plasminogen and antiplasmin in plasma and serum of 65 paired samples. The micromolar concentrations (in parentheses) are obtained from a plasminogen concentration of 14.6 mg/dl determined by radial immunodiffusion and from the reported12 micromolar concentration for alpha-2-antiplasmin

<table>
<thead>
<tr>
<th></th>
<th>Plasma concentration (%) and μmol/l</th>
<th>Serum concentration (%) and μmol/l</th>
<th>Difference (%) and μmol/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasminogen (functional)</td>
<td>99.0 ± 13.8 (1.6)</td>
<td>62.8 ± 9.9 (0.99)</td>
<td>37.9 ± 10.4 (0.61)</td>
</tr>
<tr>
<td>Plasminogen (antigenic)</td>
<td>104.6 ± 23 (1.67)</td>
<td>89.0 ± 13.9 (1.41)</td>
<td>15.6 ± 4.1 (0.26)</td>
</tr>
<tr>
<td>Antiplasmin (functional)</td>
<td>99.8 ± 10.9 (1.0)</td>
<td>69.4 ± 9.9 (0.68)</td>
<td>32.3 ± 11.0 (0.32)</td>
</tr>
</tbody>
</table>

Table 2 Difference in plasminogen concentrations when pooled plasma (n=65) was clotted in the presence and absence of 180 mmol/l 6-aminoheptanoic acid (6-AHA). Each value is the mean of four determinations

<table>
<thead>
<tr>
<th></th>
<th>Pooled plasma with added 6-AHA</th>
<th>Pooled serum with added 6-AHA</th>
<th>Pooled serum prepared with 6-AHA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasminogen concentration (as % of plasma)</td>
<td>100</td>
<td>60</td>
<td>74</td>
</tr>
</tbody>
</table>
Concentration of plasminogen and antiplasmin in plasma and serum

the blood samples and to Mr N Jones, KabiVitrum, for the gift of the antiplasmin assay kits used in this study.

References


Requests for reprints to: Dr SA Cederholm-Williams, Department of Haematology, John Radcliffe Hospital, Oxford OX3 9DU, England.